|
| Authors | N of patients | % Women | Mean age (years), mean (SD or range) | Ethnicity or countries of origin | % of pSS cases | % of sSS cases or other diseases |
|
| Baldini et al. [6] | NR as a nonsystematic review |
|
| Vitali et al. [7] | NR as a nonsystematic review |
|
| Vitali et al. [8] | 480 | 48.54% (pSS)
39.37% (sSS) | 54 ± 14 (pSS)
56 ± 13 (sSS) | 11 European countries plus Israel (descriptive statistics are not shown) | 51.25% | 41.87% |
|
| Vitali et al. [9] | 180 | 41.11% (pSS) | 58.1 ± 14.9 (pSS) | 10 European countries (descriptive statistics are not shown) | 42.22% | No distinction between pSS and sSS |
|
| Shiboski et al. [10] | 1,618 | 92.27% | 54 (21–90) | Argentina (17%), China (15%), Denmark (20%), Japan (15%), United Kingdom (7%), USA (26%) | No distinction between pSS and sSS | No distinction between pSS and sSS |
|
| Rasmussen et al. [11] | 837 | 91% | 55 (12–86) | Caucasian (74%), African-American (2%), Asian (1%), Native American (2%), Pacific Islander (0.1%) | No distinction between pSS and sSS | No distinction between pSS and sSS |
|
| Van Nimwegen et al. [12] | 114 | 94% (pSS)
86% (sSS) | 52.3 ± 15.3 (pSS)
50.2 ± 12.6 (sSS) | Netherlands (descriptive statistics are not shown) | 29.82% | 70.17% |
|
| Shiboski et al. [13] | 1,578 | NR | NR | Argentina, China, Denmark, Japan, United Kingdom, USA (descriptive statistics are not shown) | No distinction between pSS and sSS | No distinction between pSS and sSS |
|
| Rasmusssen et al. [14] | 1,703 | 93.3% (SS) | 56.5 (47–65) (SS) | Caucasian (65.2%), African-American (3.6%), native American (27.2%), Asian (2.9%) | 26.13% | No distinction between pSS and sSS |
|
| Billings et al. [15] | 1,303 | 92.2% (SS) | 53 (7–81) (SS) | Caucasian (74.2%), African-American (11.9%), Asian (7.2%), other (6.7%) | 53.80% | No distinction between pSS and sSS |
|
| Bautista-Vargas et al. [16] | NR as a nonsystematic review |
|
| Wijaya et al. [17] | 23 | 91.30% (pSS) | 50.2 (40.6–73.4%) | NR | 39.13% | No distinction between pSS and sSS |
|
| Chisholm et al. [18] | 40 | 20% (pSS) | 65 (pSS) | NR | 25% | 25% (rheumatoid arthritis)
15% (Osteoarthritis)
15% (Reiter’s disease)
10% (psoriatic arthritis)
10% (scleroderma) |
|
| Greenspan et al. [19] | 43 | NR | NR | NR | 100% | No distinction between pSS and sSS |
|
| Fox et al. [20] | NR |
|
| Marx et al. [21] | 77 | NR | NR | African-American (35.06%), Caucasian (5.19%) | 46.75% (SS) | 40.26% (sarcoidosis)
6.49% (sialosis)
6.49% (lymphoma) |
|
| Delgado et al. [22] | 19 | 36.84% | 32 | Peru (100%) | 0% | 100% (secondary amyloidosis) |
|
| Richards et al. [23] | 58 | NR | 20–72 | UK (100%) | 0% | 100% (secondary amyloidosis) |
|
| Seoane et al. [24] | NR |
|
| Peloro et al. [25] | NR |
|
| Guevara-Gutiérrez et al. [26] | 50 | NR | NR | NR | 100% (SS) | 0% |
|
| Teppo et al. [27] | 191 | 81% | 53 (20–85) | Finland (100%) | 38% (SS) | 63% (non-SS) |
|
| Comini et al. [28] | 569 | NR | NR | Italy (100%) | NR | NR |
|
| Syed et al. [29] | 400 | NR | NR | Canada (descriptive statistics are not shown) | NR | NR |
|
| Friedman et al. [30] | NR |
|
| Tarpley et al. [31] | 96 | NR | NR | USA (descriptive statistics are not shown) | NR | NR |
|
| Costa et al. [32] | 166 | NR | NR | France (descriptive statistics are not shown) | NR | NR |
|
| Chen et al. [33] | 28 | 92.86% (SS)
100% (non-SS) | 44.86 ± 11.18 (SS)
47.71 ± 8.09 (non-SS) | NR | 50% (SS) | 50% (non-SS) |
|
| Daniels et al. [34] | 1787 | 93% | 54 (21–90) | USA (26%), Denmark (20%), Argentina (17%), Japan (15%), China (15%), UK (7%) | NR | 5% (sSS) |
|
| Barone et al. [35] | NR as a nonsystematic review |
|
| Han et al. [36] | 1 (case report) | 100% | 55 | China (100%) | 100% (SS) | 100% (AOSD) |
|
| Kapsogeorgou et al. [37] | NR as a nonsystematic review |
|
| Rooper et al. [38] | NR as a nonsystematic review |
|
| Carubbi et al. [39] | 104 | 94.23% | 52 | NR | 100% | 0% |
|
| Fragkioudaki et al. [40] | 473 | 94.49% (pSS)
100% (pSS NHL)
91.78% (pSS NHL MALT) | 51.6 ± 13.2 (pSS)
52.1 ± 16.2 (pSS NHL)
49.9 ± 12.7 (pSS NHL MALT) | Greece (100%) | 80.55% (pSS) | 4.02% (pSS NHL)
15.43% (pSS NHL MALT) |
|
| Berardicurti et al. [41] | NR as a systematic review |
|
| Stergiou et al. [42] | NR as a nonsystematic review |
|
